)
)
ALX Oncology Holdings Inc Investor Relations Material
Latest events
Study Update
ALX Oncology Holdings Inc
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from ALX Oncology Holdings Inc
Access all reports
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that target the CD47 checkpoint pathway, which plays a critical role in cancer cells' ability to evade the immune system. The company's lead product candidate, evorpacept, is designed to block CD47 and is being developed in combination with other anti-cancer agents. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for ALX Oncology Holdings Inc
Corporate Presentation
ALX Oncology Holdings Inc
Corporate Presentation
ALX Oncology Holdings Inc
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
ALXO
Country
🇺🇸 United States